Cellyan Biotechnology Co., Ltd (HKPD)
NASDAQ: HKPD · Real-Time Price · USD
0.5675
-0.0010 (-0.18%)
At close: Apr 1, 2026, 4:00 PM EDT
0.5700
+0.0025 (0.44%)
After-hours: Apr 1, 2026, 4:43 PM EDT
Cellyan Biotechnology Revenue
Cellyan Biotechnology had revenue of $7.14M in the half year ending September 30, 2025, with 1.83% growth. This brings the company's revenue in the last twelve months to $16.36M, down -21.23% year-over-year. In the fiscal year ending March 31, 2025, Cellyan Biotechnology had annual revenue of $20.31M with 21.72% growth.
Revenue (ttm)
$16.36M
Revenue Growth
-21.23%
P/S Ratio
0.80
Revenue / Employee
$605,917
Employees
27
Market Cap
13.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 20.31M | 3.63M | 21.72% |
| Mar 31, 2024 | 16.69M | 4.13M | 32.91% |
| Mar 31, 2023 | 12.56M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionHKPD News
- 2 months ago - Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency - GlobeNewsWire
- 3 months ago - Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders - GlobeNewsWire
- 4 months ago - DCS Announces Q3 2025 Quarterly Financial Statements - Newsfile Corp
- 1 year ago - Hong Kong Pharma Digital Technology Holdings Limited Reports Financial Results for the Six Months Ended September 30, 2024 - PRNewsWire
- 1 year ago - Hong Kong Pharma Digital Technology Holdings Limited Announces Closing of Initial Public Offering - PRNewsWire